Pacific Biosciences is trading 10.8% down at $1.28 as investors de-risk ahead of its Q2 2026 earnings report scheduled for release this afternoon.
- Market participants appear cautious regarding Revio system adoption, revenue growth trajectories, and the company's ongoing losses.
- The sharp selloff comes despite a generally positive backdrop for the biotech sector and mixed performance in the broader market.